SVB Leerink analyst Marc Goodman says everything he heard from Evolus management during recent investor meetings increased his confidence that Jeuveau will continue to ramp up nicely this year. Further, the analyst still believes that the most likely outcome for the International Trade Commission litigation is a settlement. Goodman, who remains focused on the Jeuveau fundamentals, continues to like shares of Evolus at current levels and maintains an Outperform rating on the name with a $25 price target.

Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Renalytix... To see the rest of the story go to thefly.com. See Story Here

Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSQualtrics... To see the rest of the story go to thefly.com. See Story Here

SVB Leerink, Stifel and Cantor are acting as joint bookrunning managers for the offering.